Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury
- VernacularTitle:早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展
- Author:
Ge YANG
1
;
Jun YANG
2
;
Fang LIU
3
;
Yongchuan CHEN
2
;
Hong ZHANG
1
Author Information
1. Dept. of Pharmacy，Renmin Hospital of Wuhan University，Wuhan 430060，China
2. Dept. of Pharmacy，the First Affiliated Hospital of AMU，Chongqing 400038，China
3. Dept. of Pharmacy，Daping Hospital of AMU，Chongqing 400042，China
- Publication Type:Journal Article
- Keywords:
novel biomarkers;
polymyxin;
acute kidney injury;
nephrotoxicity;
early prediction
- From:
China Pharmacy
2025;36(2):251-256
- CountryChina
- Language:Chinese
-
Abstract:
Polymyxin is an essential antibiotic for treating multidrug-resistant Gram-negative bacterial infections； however， its significant nephrotoxicity greatly limits its clinical application. To enhance its safety and improve patient outcomes， the study of novel biomarkers for the early prediction of polymyxin-associated acute kidney injury is critically important. Novel biomarkers， such as cystatin C， kidney injury molecule-1， neutrophil gelatinase-associated lipocalin， N-acetyl-β-glucosaminidase， β2- microglobulin， have shown obvious advantages in the early prediction of polymyxin-associated acute kidney injury. Compared to traditional biomarkers， these biomarkers can provide sensitive and specific diagnostic information in the early stages of kidney injury， helping to optimize individualized treatment plans and reduce clinical risks. However， the high cost of detection and complex operation still limit their clinical promotion. Future research should focus on optimizing the detection technology of new biomarkers， simplifying the operation process and reducing costs， while conducting multi-center， large-scale randomized controlled trials to systematically evaluate the sensitivity and specificity of various novel biomarkers， in order to promote their application in the field of prediction of renal injury in clinical practice.
